Robot model
Senhance
Asensus Surgical, formerly TransEnterix and based in Durham, North Carolina, was a public company on the NYSE American as ASXC that made the Senhance…
- Manufacturer
- Asensus Surgical
- Form factor
- surgical
- Maturity
- commercial
- Lifecycle
- active
- Deployments
- 2
Overview
Asensus Surgical, formerly TransEnterix and based in Durham, North Carolina, was a public company on the NYSE American as ASXC that made the Senhance multi-port laparoscopic robotic system, FDA-cleared via 510(k) in October 2017 with subsequent instrument and indication clearances, making Senhance a genuinely cleared if relatively low-volume commercial product. The headline current-state fact is that Karl Storz acquired the company, closing on August 22, 2024 at $0.35 per share for about $95 million, a roughly 67 percent premium, with the stock ceasing to trade on the NYSE American at close, leaving Asensus a private Karl Storz subsidiary; this is the canonical example of a large medtech company absorbing a struggling robotics startup for a fraction of its historic enterprise value. The registry records Senhance at commercial maturity with an active lifecycle, since it remains a cleared product line continuing under Karl Storz, while the company status is recorded as acquired. The company's next-generation LUNA system, unveiled in February 2023 with claimed real-time clinical intelligence and cloud machine learning, was not FDA-submitted, not cleared, and not for sale as of the August 2024 close, so LUNA is recorded at research maturity, with a 2025 FDA target that is unverified as met and a current status under private ownership that is not publicly traceable. On AI substance the cleared digital-surgery features are machine-vision and digital-laparoscopy assists that are real but incremental rather than autonomy, and the Performance-Guided Surgery framing was oversold relative to what is cleared.
Verified vs. claimed
- Maturity stage
- commercial(Commercially deployed with revenue-generating operations.)
- Verified deployments
- 2 deployments on file
- Sources on file
- 4 sources, view all
Key facts
Acquisition price
Acquisition close date
FDA clearance date
LUNA unveiling date
LUNA FDA target
Specs
Notes
Products
Form Factor
Fda clearance
Clearance body
Procedure types
Data & sources
Press releases
1
News coverage
1
Web sources
2
4 sources backing this record.View all →
Pricing
No verified price is on record for Senhance. Physical-AI systems are often sold through enterprise contracts or operated as a service rather than at a public list price.
Deployments (2)
- Senhance at United Statesoperational
The Senhance system received FDA 510(k) clearance in 2017 for laparoscopic procedures and pediatric clearance in March 2023, with limited US adoption across approximately 5 or more hospitals.
- Senhance at European Unionoperational
The Senhance digital surgical system has been deployed at multiple EU hospitals, including Klinikum Idar-Oberstein in Germany, which initiated a Senhance surgery program, and LMU Klinikum in Munich, where the system was…
Senhance on the deployment map
Where Senhance is verified operating. Explore the deployment map by place and type.
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Verified media addedVerifiedJun 5, 2026
Asensus Senhance digital laparoscopy
- Record createdJun 3, 2026
Added to the verified registry
- Price point recordedJun 1, 2024
Not announced
- Incident recordedSep 15, 2023
Asensus Senhance Class I recall: software malfunction caused uncontrolled arm motion...
- Deployment verifiedVerifiedJan 1, 2017
at United States
Deployment-verified media (1)
Asensus Surgical footage of its Senhance digital-laparoscopy system in a simulation and training environment (not a live clinical case). A surgeon-teleoperated system, not autonomous.
From deployment: European Union
Components (1)
Instrument arm
- actuator failure · critical: FDA recall after reports of unintended/uncontrolled arm movement; device correction.
Components carry componentClass + safetyCritical flag. ModelComponent rows carry safety_role (primary_safety / backup_safety / monitoring / non_safety) + optional supplier identity.
Regulatory filings (3)
- fda_recallfda recall · us_fdarecalled2023-09-15
Applicant: Asensus Surgical
- fda_510kfda 510k · us_fdacleared2023-01-01
Applicant: Asensus Surgical
- K171120fda 510k · us_fdacleared2017-04-14
Applicant: Asensus Surgical
Safety record
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Incidents affecting Senhance (1)
Includes incidents linked directly to this model or to deployments of it. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.
Sources (4)
- https://www.globenewswire.com/news-release/2024/08/22/asensus-surgical-karl-storz-closing
- https://www.massdevice.com/asensus-surgical-karl-storz-acquisition/
- https://www.urologytimes.com/view/transenterix-senhance-fda-clearance
- https://www.therobotreport.com/karl-storz-closes-acquisition-of-asensus-surgical/
Common questions
- What is Senhance?
- Asensus Surgical, formerly TransEnterix and based in Durham, North Carolina, was a public company on the NYSE American as ASXC that made the Senhance multi-port laparoscopic robotic system, FDA-cleared via 510(k) in October 2017 with subsequent instrument and indication clearances, making Senhance a genuinely cleared if relatively low-volume commercial product. The headline current-state fact is that Karl Storz acquired the company, closing on August 22, 2024 at $0.35 per share for about $95 million, a roughly 67 percent premium, with the stock ceasing to trade on the NYSE American at close, leaving Asensus a private Karl Storz subsidiary; this is the canonical example of a large medtech company absorbing a struggling robotics startup for a fraction of its historic enterprise value. The registry records Senhance at commercial maturity with an active lifecycle, since it remains a cleared product line continuing under Karl Storz, while the company status is recorded as acquired. The company's next-generation LUNA system, unveiled in February 2023 with claimed real-time clinical intelligence and cloud machine learning, was not FDA-submitted, not cleared, and not for sale as of the August 2024 close, so LUNA is recorded at research maturity, with a 2025 FDA target that is unverified as met and a current status under private ownership that is not publicly traceable. On AI substance the cleared digital-surgery features are machine-vision and digital-laparoscopy assists that are real but incremental rather than autonomy, and the Performance-Guided Surgery framing was oversold relative to what is cleared.
- How much does Senhance cost?
- Senhance's price is not publicly disclosed. DEPLOY has no verified price on record for Senhance from Asensus Surgical. Physical-AI systems like this are often sold through enterprise contracts or operated as a service rather than at a public list price; check the manufacturer for the latest.
- Is Senhance actually deployed in the real world?
- Yes. Senhance is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.
- Is Senhance autonomous or teleoperated?
- Not verified as fully autonomous. Senhance's capabilities on the DEPLOY registry are recorded as teleoperated-assisted, demonstrated-only, or vendor claims (Assists surgery), not independently confirmed to run without a human in the loop.
- Who makes Senhance?
- Senhance is made by Asensus Surgical, based in Durham, NC, founded in 2006.
- Where is Senhance deployed?
- 2 verified deployments of Senhance are on the DEPLOY registry, including at United States, European Union.
- Can you buy Senhance?
- Senhance is in commercial deployment and is sold to operators; contact the manufacturer to buy, and see the pricing section for any recorded price.
- Is Senhance FDA cleared?
- Senhance has 3 regulatory records on the DEPLOY registry: FDA recall, recalled; FDA 510(k) clearance, cleared; FDA 510(k) clearance (K171120), cleared. See the Regulatory filings section for each agency source.
- What are alternatives to Senhance?
- On the DEPLOY registry, comparable surgical robots to Senhance include Toumai, da Vinci (and Ion), Epione, Hugo RAS.
- How does Senhance compare to Toumai?
- Senhance and Toumai (MicroPort MedBot · 8 deployments) are both surgical robots on the DEPLOY registry. Senhance has 2 verified deployments on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.
- Is Senhance a top surgical?
- On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Senhance ranks in roughly the top 38% of surgical models tracked by the registry.
- What is Senhance's maturity stage?
- Senhance is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.
- Is Senhance safe?
- Senhance has 1 active incident on record in the DEPLOY registry. 1 recall on record (1 critical). Most recent: Sep 2023. Retracted incidents are excluded from this count.
- What is the Asensus Senhance surgical robot?
- The Asensus Senhance is a robotic surgical system that empowers surgeons with real-time insights. The FDA issued a Class I recall (the most serious type) for the Senhance system due to malfunctions causing unintended movement. Class I recalls may cause serious injuries or death.
Methodology: Verified · 4 sources (1 primary) · last reviewed 2026-07-12
Verification posture
Verified
High confidence
Review state
Stable
Last reviewed 2026-07-12
Maturity + lifecycle
Maturity stage: commercial
Lifecycle: active
Architectural position
Cohort: surgical
Sources by quality tier
- 2
- unclassified
- Unclassified source
- 1
- primary-company-ir
- Company IR disclosure
- 1
- secondary-trade-publication
- Trade publication
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Senhance.Recent coverage
Senhance in third-party press
Attention vs reality over time
Media mentions per month (area) against verified deployment events (dots). A press spike over a flat deployment line is the hype gap, drawn over time.
In the press
Recent coverage mentioning Senhance from third-party publications. Automatically surfaced; not part of the verified registry record.
Karl Storz to fully integrate Asensus, discontinue Senhance
KARL STORZ acquired Asensus Surgical for 35 cents per share, fully integrating the company, retiring the Senhance platform, discontinuing Luna development, and sunsetting the…
Asensus Senhance surgical robot receives FDA 510(k) clearance
Asensus Surgical's Senhance Surgical System received FDA 510(k) clearance, enabling the digital laparoscopic platform for use in U.S. hospitals.
Machine-readable surfaces
- Markdown mirror: /models/asensus-senhance.md
- JSON-LD: embedded in this page’s head
- REST API: /v1/models/abadf566-b528-4b44-be3e-418ca078e920
- Revision history: /models/asensus-senhance/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Video
Rich DeMuro takes a look at a new type of “microsurgery” robot that can help doctors operate on blood vessels thinner than a human hair. More Rich: https://ktl
SHURUI.The world’s first single-port surgical robot with snake-like arms applied to the human body. This is our new project based on our Uniportal technique wit
A first Impressions review of the Asensus Luna surgical robot. Built from reviewing the lab work presentation. First impressions of this early prototype. The co
President and CEO of TransEnterix Inc., Todd Pope, joins Neal Howard on Health Professional Radio to talk about the recent FDA clearance of their company’s inve
Learn more from Dr. Amit Trivedi and Dr. Sarah Wong about the Senhance robotic surgery program at Pascack Valley Medical Center.
Designed with learning in mind, Senhance® Simulation allows surgeons to develop fundamental skills with the Senhance® Surgical System in a safe and flexible env
Asensus-hosted webinar in collaboration with the International Pediatric Endosurgery Group (IPEG).
CEO Anthony Fernando shared years ago that while the robot is important, performance-guided surgery that is empowered by real-time surgical insights and powered
In the latest episode of DeviceTalks AI, President and CEO of Asensus Surgical, Anthony Fernando walks us through the significant differences between augmented
What if the future of surgery isn’t just human hands… but robots guiding every movement with microscopic precision? 🤖 From AI-powered surgical systems to robo
Reality vs attention
Senhance draws attention at the 54th percentile but verifies reality at the 71st percentile among surgical robots. Hype Gap -16.9, 18th widest among surgical robots.
6-month trend
Analysis
Thin deployment record; scale validation still in progress.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Jul 18, 2026